Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.4240
-0.0092 (-2.12%)
At close: Apr 23, 2026, 4:00 PM EDT
0.4330
+0.0090 (2.12%)
After-hours: Apr 23, 2026, 7:16 PM EDT
Ensysce Biosciences Revenue
In the year 2025, Ensysce Biosciences had annual revenue of $5.07M, down -2.75%. Ensysce Biosciences had revenue of $1.88M in the quarter ending December 31, 2025, with 44.39% growth.
Revenue (ttm)
$5.07M
Revenue Growth
-2.75%
P/S Ratio
0.77
Revenue / Employee
$506,665
Employees
10
Market Cap
3.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.07M | -143.38K | -2.75% |
| Dec 31, 2024 | 5.21M | 2.98M | 133.58% |
| Dec 31, 2023 | 2.23M | -292.86K | -11.61% |
| Dec 31, 2022 | 2.52M | -1.01M | -28.54% |
| Dec 31, 2021 | 3.53M | -400.01K | -10.18% |
| Dec 31, 2020 | 3.93M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 11.51M |
| Moolec Science | 7.83M |
| CollPlant Biotechnologies | 2.37M |
| 60 Degrees Pharmaceuticals | 1.41M |
| VivoSim Labs | 142.00K |
| AIM ImmunoTech | 88.00K |
| Pulmatrix | 3.00K |
ENSC News
- 7 days ago - Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study - Accesswire
- 16 days ago - Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs - Accesswire
- 24 days ago - Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - Accesswire
- 7 weeks ago - Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans - Accesswire
- 7 weeks ago - Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology - Accesswire
- 7 weeks ago - Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review - Benzinga
- 2 months ago - Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value - Accesswire
- 2 months ago - Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events - Accesswire